$CLDX California State Teachers Retirement System
Post# of 22755
Posted On: 04/01/2016 7:45:42 PM
$CLDX California State Teachers Retirement System Increases Position in Celldex Therapeutics, Inc. (CLDX)
Posted by Leslie Fiani on Apr 1st, 2016 // No Comments
Celldex Therapeutics logoCalifornia State Teachers Retirement System raised its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 1.6% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 182,509 shares of the biopharmaceutical company’s stock after buying an additional 2,946 shares during the period. California State Teachers Retirement System owned about 0.19% of Celldex Therapeutics worth $2,862,000 as of its most recent filing with the SEC.
A number of other hedge funds have also made changes to their positions in CLDX. DekaBank Deutsche Girozentrale boosted its stake in shares of Celldex Therapeutics by 1.0% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 50,100 shares of the biopharmaceutical company’s stock valued at $808,000 after buying an additional 500 shares during the last quarter. Nationwide Fund Advisors boosted its stake in shares of Celldex Therapeutics by 22.3% in the fourth quarter. Nationwide Fund Advisors now owns 115,044 shares of the biopharmaceutical company’s stock valued at $1,804,000 after buying an additional 20,996 shares during the last quarter. Finally, Rhenman & Partners Asset Management boosted its stake in shares of Celldex Therapeutics by 8.5% in the fourth quarter. Rhenman & Partners Asset Management now owns 320,000 shares of the biopharmaceutical company’s stock valued at $5,018,000 after buying an additional 25,000 shares during the last quarter.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) traded up 4.50% during trading on Friday, reaching $3.95. 2,787,859 shares of the company’s stock were exchanged. The stock has a 50-day moving average price of $5.32 and a 200 day moving average price of $11.34. Celldex Therapeutics, Inc. has a 52 week low of $2.96 and a 52 week high of $30.28. The firm’s market capitalization is $389.88 million.
Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Thursday, February 25th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.02. The business had revenue of $1.80 million for the quarter, compared to analysts’ expectations of $0.80 million. The business’s revenue was up 21.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.36) earnings per share. Equities research analysts forecast that Celldex Therapeutics, Inc. will post ($1.33) earnings per share for the current fiscal year.
Several analysts have commented on CLDX shares. Brean Capital restated a “buy” rating and set a $24.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, March 8th. HC Wainwright assumed coverage on shares of Celldex Therapeutics in a research note on Tuesday, March 1st. They set a “buy” rating and a $25.00 price objective for the company. Cantor Fitzgerald decreased their target price on shares of Celldex Therapeutics from $31.00 to $25.00 and set a “buy” rating for the company in a research note on Friday, February 26th. Roth Capital reiterated a “buy” rating on shares of Celldex Therapeutics in a research note on Tuesday, March 8th. Finally, Jefferies Group cut shares of Celldex Therapeutics from a “buy” rating to a “hold” rating and decreased their target price for the company from $31.00 to $4.00 in a research note on Monday, March 7th. Seven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $20.00.
Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.
12 Month Chart for NASDAQ:CLDX
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.co
Posted by Leslie Fiani on Apr 1st, 2016 // No Comments
Celldex Therapeutics logoCalifornia State Teachers Retirement System raised its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 1.6% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 182,509 shares of the biopharmaceutical company’s stock after buying an additional 2,946 shares during the period. California State Teachers Retirement System owned about 0.19% of Celldex Therapeutics worth $2,862,000 as of its most recent filing with the SEC.
A number of other hedge funds have also made changes to their positions in CLDX. DekaBank Deutsche Girozentrale boosted its stake in shares of Celldex Therapeutics by 1.0% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 50,100 shares of the biopharmaceutical company’s stock valued at $808,000 after buying an additional 500 shares during the last quarter. Nationwide Fund Advisors boosted its stake in shares of Celldex Therapeutics by 22.3% in the fourth quarter. Nationwide Fund Advisors now owns 115,044 shares of the biopharmaceutical company’s stock valued at $1,804,000 after buying an additional 20,996 shares during the last quarter. Finally, Rhenman & Partners Asset Management boosted its stake in shares of Celldex Therapeutics by 8.5% in the fourth quarter. Rhenman & Partners Asset Management now owns 320,000 shares of the biopharmaceutical company’s stock valued at $5,018,000 after buying an additional 25,000 shares during the last quarter.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) traded up 4.50% during trading on Friday, reaching $3.95. 2,787,859 shares of the company’s stock were exchanged. The stock has a 50-day moving average price of $5.32 and a 200 day moving average price of $11.34. Celldex Therapeutics, Inc. has a 52 week low of $2.96 and a 52 week high of $30.28. The firm’s market capitalization is $389.88 million.
Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Thursday, February 25th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.02. The business had revenue of $1.80 million for the quarter, compared to analysts’ expectations of $0.80 million. The business’s revenue was up 21.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.36) earnings per share. Equities research analysts forecast that Celldex Therapeutics, Inc. will post ($1.33) earnings per share for the current fiscal year.
Several analysts have commented on CLDX shares. Brean Capital restated a “buy” rating and set a $24.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, March 8th. HC Wainwright assumed coverage on shares of Celldex Therapeutics in a research note on Tuesday, March 1st. They set a “buy” rating and a $25.00 price objective for the company. Cantor Fitzgerald decreased their target price on shares of Celldex Therapeutics from $31.00 to $25.00 and set a “buy” rating for the company in a research note on Friday, February 26th. Roth Capital reiterated a “buy” rating on shares of Celldex Therapeutics in a research note on Tuesday, March 8th. Finally, Jefferies Group cut shares of Celldex Therapeutics from a “buy” rating to a “hold” rating and decreased their target price for the company from $31.00 to $4.00 in a research note on Monday, March 7th. Seven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $20.00.
Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.
12 Month Chart for NASDAQ:CLDX
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.co
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼